Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.39 |
| ▸ | HMGCR | P04035 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424871 | 1.00 | KCNH2 (0.46) | KCNH2PTPN7HMGCRGPR84FFAR1 | |
| SCHEMBL30770107 | 0.75 | KCNH2 (0.51) | KCNH2PTPN7HMGCRGPR84FFAR1 | |
| SCHEMBL9374800 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL1523678 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL513302 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL23040316 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL11175213 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL11066113 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL10796010 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL9211891 | 0.72 | PTPN7 (0.61) | KCNH2PTPN7HMGCRRECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361915-B1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-8313671-B2 | Heterocyclic compound and use thereof | HIROSHIMA UNIVERSITY (JP) | 2012-11-20 | — | — | US | disclosed |
| US-8313671-B2 | Heterocyclic compound and use thereof | HIROSHIMA UNIVERSITY (JP) | 2012-11-20 | — | — | US | disclosed |
| EP-2361915-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | Hiroshima University (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20110204295-A1 | Novel Heterocyclic Compound And Use Thereof | HIROSHIMA UNIVERSITY (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110204295-A1 | Novel Heterocyclic Compound And Use Thereof | HIROSHIMA UNIVERSITY (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110204295-A1 | Novel Heterocyclic Compound And Use Thereof | SCLY, C9, C1S | KCNH2 1369/4885PTPN7 2548/4885HMGCR 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.